公开(公告)号：US20240252516A1

公开(公告)日：2024-08-01

申请号：US18161922

申请日：2023-01-31

申请人： Nymox Corporation

发明人： Paul Averback

IPC分类号： A61K31/58 ,  A61K31/18 ,  A61K38/10 ,  A61K45/06 ,  A61P13/08

CPC分类号： A61K31/58 ,  A61K31/18 ,  A61K38/10 ,  A61K45/06 ,  A61P13/08

摘要： Disclosed are methods of treating benign prostatic hyperplasia that include administering a composition containing at least Fexapotide Triflutate (FT), and subsequently administering one or more compositions containing a 5 α-reductase inhibitor (5-ARI) and an alpha1-adrenergic receptor blocker (alpha blocker). The methods provide dramatically improved mean IPSS values, when compared to the average mean IPSS of the individual actives alone, or when compared to the average mean IPSS of (a) the composition containing FT; and (b) the combination of 5-ARI and alpha blocker.

公开(公告)号：US20170020957A1

公开(公告)日：2017-01-26

申请号：US14808731

申请日：2015-07-24

申请人： Nymox Corporation

发明人： Paul Averback

IPC分类号： A61K38/17

CPC分类号： A61K38/17 ,  A61K38/10

摘要： The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof. Carrying out the method unexpectedly reduces the need for subsequent invasive surgical intervention.

摘要翻译： 实施方案包括使用基于小肽与其它活性剂组合的化合物来治疗需要除去或破坏细胞元件如良性或恶性肿瘤的病症的方法。 该方法包括但不限于单独或与载体缀合至有需要的哺乳动物肌肉内，口服，静脉内，鞘内，肿瘤内，鼻内，局部，经皮等的化合物。 意外地执行该方法减少了后续侵入性外科手术的需要。

公开(公告)号：US20220323543A1

公开(公告)日：2022-10-13

申请号：US17740755

申请日：2022-05-10

申请人： Nymox Corporation

发明人： Paul Averback

IPC分类号： A61K38/17 ,  A61P35/00

摘要： The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.

公开(公告)号：US20220226424A1

公开(公告)日：2022-07-21

申请号：US17557951

申请日：2021-12-21

申请人： Nymox Corporation

发明人： Paul AVERBACK

IPC分类号： A61K38/10 ,  A61P13/08

摘要： Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

公开(公告)号：US11278588B2

公开(公告)日：2022-03-22

申请号：US16410658

申请日：2019-05-13

申请人： Nymox Corporation

发明人： Paul Averback

IPC分类号： A61K38/00 ,  A61K38/10 ,  A61P13/02

摘要： Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient. The methods are particularly effective in improving urinary peak flow (Qmax), and in improving nocturia.

公开(公告)号：US20210033613A1

公开(公告)日：2021-02-04

申请号：US16528390

申请日：2019-07-31

申请人： NYMOX CORPORATION

发明人： Paul AVERBACK

IPC分类号： G01N33/574

摘要： The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.

公开(公告)号：US20160361380A1

公开(公告)日：2016-12-15

申请号：US14738551

申请日：2015-06-12

申请人： Nymox Corporation

发明人： Paul AVERBACK

IPC分类号： A61K38/10 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/404 ,  A61K9/00 ,  A61K31/18

CPC分类号： A61K38/10 ,  A61K9/0053 ,  A61K31/18 ,  A61K31/404 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/58 ,  A61K38/1709 ,  A61K45/06 ,  A61K2300/00

摘要： The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intraprostatically, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.

摘要翻译： 实施方案包括使用基于小肽与其它活性剂组合的化合物来治疗需要除去或破坏细胞元件如良性或恶性肿瘤的病症的方法。 该方法包括但不限于单独或与载体缀合至有需要的哺乳动物肌内，口服，静脉内，鞘内，经内皮，肿瘤内，鼻内，局部，经皮等方式的化合物。

公开(公告)号：US12090191B2

公开(公告)日：2024-09-17

申请号：US17557951

申请日：2021-12-21

申请人： Nymox Corporation

发明人： Paul Averback

IPC分类号： A61K38/00 ,  A61K38/10 ,  A61P13/08

CPC分类号： A61K38/10 ,  A61P13/08

摘要： Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

公开(公告)号：US11298400B2

公开(公告)日：2022-04-12

申请号：US16410639

申请日：2019-05-13

申请人： Nymox Corporation

发明人： Paul Averback

IPC分类号： A61K38/00 ,  A61K38/10 ,  A61P13/08

摘要： Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

公开(公告)号：US11231421B2

公开(公告)日：2022-01-25

申请号：US16528390

申请日：2019-07-31

申请人： NYMOX CORPORATION

发明人： Paul Averback

IPC分类号： A61P35/00 ,  A61K38/00 ,  G01N33/574

摘要： The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.